MAPT and Alzheimer disease: Recently, distinct spatiotemporal trajectories of tau pathology, brain atrophy, postmortem brain transcriptomics profiles, or cerebrospinal fluid proteomics have been associated with multiple clinical and pathological AD features [1–10].